SMIN

2,536

+0.67%↑

SMIN

2,536

+0.67%↑

SMIN

2,536

+0.67%↑

SMIN

2,536

+0.67%↑

SMIN

2,536

+0.67%↑

Search

Syncona Ltd

Closed

85.5 -1.04

Overview

Share price change

24h

Current

Min

85.2

Max

87

Key metrics

By Trading Economics

Income

-25M

Sales

20M

Profit margin

-127.345

Employees

1,215

EBITDA

-25M

Dividends

By Dow Jones

Next Earnings

18 Jun 2026

Market Stats

By TradingEconomics

Market Cap

536M

Previous open

86.54

Previous close

85.5

Syncona Ltd Chart

Past performance is not a reliable indicator of future results.

Related News

29 Apr 2026, 23:53 UTC

Earnings

Naver Posts Weaker First-Quarter Earnings

29 Apr 2026, 23:41 UTC

Hot Stocks

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 Apr 2026, 23:55 UTC

Earnings

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 Apr 2026, 23:54 UTC

Earnings

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 Apr 2026, 23:52 UTC

Earnings

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 Apr 2026, 23:51 UTC

Earnings

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 Apr 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 Apr 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 Apr 2026, 23:24 UTC

Earnings

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 Apr 2026, 23:24 UTC

Earnings

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 Apr 2026, 23:24 UTC

Earnings

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 Apr 2026, 23:24 UTC

Earnings

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 Apr 2026, 23:22 UTC

Earnings

China Longyuan 1Q Net CNY1.70B, Down 14%

29 Apr 2026, 23:22 UTC

Earnings

China Longyuan: Power Generation Down 2.9% as of End-March

29 Apr 2026, 23:20 UTC

Earnings

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 Apr 2026, 23:20 UTC

Earnings

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 Apr 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 Apr 2026, 23:19 UTC

Earnings

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 Apr 2026, 23:19 UTC

Earnings

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 Apr 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss Narrows>000002.SZ

29 Apr 2026, 23:18 UTC

Earnings

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 Apr 2026, 23:17 UTC

Earnings

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 Apr 2026, 23:15 UTC

Earnings

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 Apr 2026, 23:15 UTC

Earnings

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 Apr 2026, 23:13 UTC

Earnings

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 Apr 2026, 23:12 UTC

Earnings

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 Apr 2026, 23:11 UTC

Earnings

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 Apr 2026, 23:11 UTC

Earnings

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 Apr 2026, 23:04 UTC

Earnings

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 Apr 2026, 23:04 UTC

Earnings

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer Comparison

Price change

Syncona Ltd Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Syncona Ltd

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
help-icon Live chat